Advisory Research’s Corcept Therapeutics CORT Stock Holding History

Advisory Research’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,087	Closed	-$643K	–	373
2022 Q3	$643K	Buy	25,087 +150	+0.6%	+$4.01K	0.06%	207
2022 Q2	$593K	Buy	+24,937	New	+$543K	0.06%	207
2018 Q1	–	Sell	-64,423	Closed	-$1.16M	–	382
2017 Q4	$1.16M	Buy	64,423 +13,398	+26%	+$243K	0.02%	264
2017 Q3	$985K	Sell	51,025 -56,411	-53%	-$841K	0.02%	312
2017 Q2	$1.27M	Sell	107,436 -52,783	-33%	-$574K	0.02%	286
2017 Q1	$1.76M	Buy	+160,219	New	+$1.41M	0.03%	263

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisory Research's CORT Position: Q4 2022 in Review

Advisory Research sold out of Corcept Therapeutics (CORT) in Q4 2022, closing a stake of 25,087 shares — an estimated $643K sold.

Advisory Research first reported a position in CORT in Q1 2017 and held it in 6 quarters. The position peaked at $1.76M in Q1 2017. 241 funds tracked by Wall St. Rank hold CORT as of Q4 2022.

Advisory Research reported no remaining Corcept Therapeutics position as of Q4 2022 after selling out during the quarter.
Advisory Research sold 25,087 Corcept Therapeutics shares in Q4 2022, an estimated $643K.
Advisory Research first reported a position in Corcept Therapeutics in Q1 2017 and held it in 6 quarters.
Advisory Research's Corcept Therapeutics position peaked at $1.76M in Q1 2017.
241 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2022.

Based on Advisory Research's 13F filing for Q4 2022, filed 13 Feb 2023.